HISAMITSU PHARMACEUTICAL CO.,INC. Logo

HISAMITSU PHARMACEUTICAL CO.,INC.

A global leader in transdermal drug delivery systems for OTC and prescription pain relief.

4530 | T

Overview

Corporate Details

ISIN(s):
JP3784600003
LEI:
Country:
Japan
Address:
鳥栖市田代大官町408番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hisamitsu Pharmaceutical Co., Inc. is a multinational pharmaceutical corporation engaged in the research, development, manufacture, and sale of prescription and over-the-counter (OTC) products. The company is a global leader in pain relief solutions, specializing in transdermal drug delivery systems. Its core portfolio features external analgesic and anti-inflammatory preparations, including well-known patches, plasters, and poultices. Hisamitsu actively pursues innovation in its field, with ongoing clinical research into next-generation technologies like microneedle drug delivery systems. Established in 1834, the company leverages its long history and expertise to market its therapeutic products worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 07:40
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 29.4 KB
2025-10-10 08:28
Registration Form
確認書
Japanese 9.2 KB
2025-10-10 08:25
Interim Report
半期報告書-第124期(2025/03/01-2026/02/28)
Japanese 240.4 KB
2025-10-03 08:43
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.7 KB
2025-09-03 08:36
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.0 KB
2025-08-05 08:45
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2025-05-23 08:00
Registration Form
確認書
Japanese 9.5 KB
2025-05-23 07:58
Governance Information
内部統制報告書-第123期(2024/03/01-2025/02/28)
Japanese 24.0 KB
2025-05-23 07:55
Registration Form
有価証券報告書-第123期(2024/03/01-2025/02/28)
Japanese 1.7 MB
2025-05-23 07:44
Post-Annual General Meeting Information
臨時報告書
Japanese 28.3 KB
2024-10-11 08:12
Registration Form
確認書
Japanese 9.2 KB
2024-10-11 08:08
Interim Report
半期報告書-第123期(2024/03/01-2025/02/28)
Japanese 244.4 KB
2024-07-12 08:12
Quarterly Report
確認書
Japanese 9.2 KB
2024-07-12 08:09
Quarterly Report
四半期報告書-第123期第1四半期(2024/03/01-2024/05/31)
Japanese 179.7 KB
2024-05-24 08:14
Registration Form
確認書
Japanese 9.5 KB

Automate Your Workflow. Get a real-time feed of all HISAMITSU PHARMACEUTICAL CO.,INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HISAMITSU PHARMACEUTICAL CO.,INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HISAMITSU PHARMACEUTICAL CO.,INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.